Cereno Scientific

According to the principles for the nomination committee that were resolved at the annual general meeting on June 1, 2023, the nomination committee should be appointed as follows. The company’s largest shareholder, or group of shareholders, as of May 31, 2023, has the right to appoint one representative of the nomination committee. Furthermore, a group of shareholders that consists of the company’s founders Sverker Jern and Niklas Bergh have the right to appoint one representative of the nomination committee. In addition, the nomination committee must include the Chair of the Board who must also be the convener.

The nomination committee ahead of the annual general meeting 2024 has thus been appointed and comprises:

• Cihan Punar, representing the company’s largest group of shareholders per May 31, 2023
• Sverker Jern, representing the Company’s founders Sverker Jern och Niklas Bergh
• Joakim Söderström, convening member and Chair of the Board of Cereno

One of the members, but not the Chair of the Board, must be appointed the Chair of the nomination committee. The nomination committee's term of office extends until a new nomination committee is appointed.

Shareholders who wish to submit proposals to the nomination committee are welcome to do so via e-mail info@cerenoscientific.com, or to the company’s postal address:

Valberedningen
Cereno Scientific AB
AstraZeneca BioVentureHub
Pepparedsleden 1
431 83 Mölndal

The proposal shall be received by the nomination committee no later than January 31, 2024. The nomination committee’s proposal will be announced in conjunction with the publication of the notice, at the latest.

For further information, please contact:

Eva Jagenheim, CFO
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.